HRP20161631T1 - Dihidropirazolni gpr40 modulatori - Google Patents
Dihidropirazolni gpr40 modulatori Download PDFInfo
- Publication number
- HRP20161631T1 HRP20161631T1 HRP20161631TT HRP20161631T HRP20161631T1 HR P20161631 T1 HRP20161631 T1 HR P20161631T1 HR P20161631T T HRP20161631T T HR P20161631TT HR P20161631 T HRP20161631 T HR P20161631T HR P20161631 T1 HRP20161631 T1 HR P20161631T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- agents
- compound
- alkyl
- independently
- Prior art date
Links
- KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole Chemical compound C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 28
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 208000031225 myocardial ischemia Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000004990 Cardiorenal syndrome Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 208000004930 Fatty Liver Diseases 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 2
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 2
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 239000002830 appetite depressant Substances 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 208000004104 gestational diabetes Diseases 0.000 claims 2
- 230000004217 heart function Effects 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 2
- 201000008980 hyperinsulinism Diseases 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 108091006269 SLC5A2 Proteins 0.000 claims 1
- 102000058081 Sodium-Glucose Transporter 2 Human genes 0.000 claims 1
- 229940125709 anorectic agent Drugs 0.000 claims 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 claims 1
- 230000001708 anti-dyslipidemic effect Effects 0.000 claims 1
- 230000001346 anti-hypertriglyceridemic effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000002253 anti-ischaemic effect Effects 0.000 claims 1
- 230000003063 anti-neuropathic effect Effects 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 230000002946 anti-pancreatic effect Effects 0.000 claims 1
- 230000002769 anti-restenotic effect Effects 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 229940125682 antidementia agent Drugs 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000006883 memory enhancing effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000002664 nootropic agent Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Optical Integrated Circuits (AREA)
Claims (15)
1. Spoj Formule (I):
[image]
ili stereoizomer, tautomer, farmaceutski prihvatljiva sol ili solvat tog spoja, gdje:
R1 je nezavisno fenil supstituiran na 0-3 R6 ili piridinil supstituiran na 0-3 R6;
R2je, pri svakom pojavljivanju, nezavisno halogen ili C1-4 alkil;
R3 je nezavisno odabran od: CF3, 4-halo-Ph, 4-CN-Ph, 4-CO2(C1-2 alkil)-Ph, 2-halo-4-CN-Ph, i pirimidin-2-il;
R4 je nezavisno C1-4 alkil ili ciklopropilmetil;
R5je, pri svakom pojavljivanju, nezavisno halogen; i
R6 pri svakom pojavljivanju, je nezavisno odabran od: OH, halogen, CN, C1-4 alkil, i C1-4 alkoksi;
i gdje spoj Formule (I) može biti izotopski obilježeno.
2. Spoj prema patentnom zahtjevu 1, gdje spoj je sa Formulom (II):
[image]
ili stereoizomer, tautomer, farmaceutski prihvatljiva sol ili solvat tog spoja,
i gdje spoj sa Formulom (II) može biti izotopski obilježeno.
3. Spoj prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, gdje:
R1 je nezavisno fenil supstituiran na 0-3 R6 ili piridinil supstituiran na 0-2 R6;
R2 je nezavisno halogen ili C1-4 alkil;
R3 je nezavisno odabran od: CF3, 4-halo-Ph, 4-CN-Ph, 4-CO2(C1-2 alkil)-Ph, 2-halo-4-CN-Ph, i pirimidin-2-il
R4 je nezavisno C1-4 alkil ili ciklopropilmetil; i
R6, pri svakom pojavljivanju, je nezavisno odabran od: halogen, CN, C1-4 alkil, i C1-4 alkoksi.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, gdje je spoj sa Formulom (III):
[image]
ili stereoizomer, tautomer, farmaceutski prihvatljiva sol ili solvat tog spoja;
i gdje spoj sa Formulom (III) može biti izotopski obilježeno.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, gdje:
R2 je nezavisno halogen ili C1-4 alkil;
R4 je nezavisno C1-4 alkil; i
R6, pri svakom pojavljivanju, je nezavisno odabran od: halogen, CN, C1-4 alkil, i C1-4 alkoksi.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5, gdje:
R2 je nezavisno halogen ili C1-4 alkil;
i
R6, pri svakom pojavljivanju, je nezavisno odabran od: halogena, C1-4 alkil, i C1-4 alkoksi.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 6, gdje:
R2 je metil;
R4 je metil; i
R6, pri svakom pojavljivanju, je nezavisno odabran od: Cl i metoksi.
8. Spoj prema patentnom zahtjevu 1, gdje je spoj odabran od:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
ili stereoizomera ili farmaceutski prihvatljive soli tog spoja.
9. Spoj prema patentnom zahtjevu 1, gdje je spoj odabran od:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
ili stereoizomera ili farmaceutski prihvatljive soli tog spoja.
10. Spoj prema patentnom zahtjevu 1, gdje je spoj odabran od:
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
ili stereoizomera ili farmaceutski prihvatljive soli tog spoja.
11. Farmaceutska kompozicija sastoji se od: farmaceutski prihvatljivog nosača i spoja iz bilo kojeg od patentnih zahtjeva 1 do 10, ili stereoizomera, tautomera, farmaceutski prihvatljive soli ili solvata tog spoja.
12. Farmaceutska kompozicija prema patentnom zahtjevu 11, dalje sadrži jedan ili više dodatnih terapijskih agenasa: anti-dijabetski agensi, anti-hiperglikemijski agensi, anti-hiperinzulinemijski agensi, anti-retinopatski agensi, anti-neuropatski agensi, anti-nefropatski agensi, anti-aterosklerotski agensi, anti-ishemijski agensi, anti-hipertenzivni agensi, agensi protiv gojaznosti, anti-dislipidemijski agensi, anti-hiperlipidemijski agensi, anti-hipertrigliceridemijski agensi, anti-hiperholesterolemijski agensi, anti-restenotski agensi, anti-pankreasni agensi, agensi za snižavanje lipida, anorektični agensi, agensi za poboljšanje memorije, agensi protiv demencije, agensi za poboljšanje kognicije, supresor apetita, tretman za srčanu slabost, tretman za perifernu arterijsku bolest i anti-inflamatorni agensi.
13. Farmaceutska kompozicija prema patentnom zahtjevu 11, dalje sadrži inhibitor dipeptidil peptidaze-IV i/ili inhibitor natrijum-glukoznog transportera 2.
14. Jedinjenja iz patentnih zahtjeva 1 do 10 za primjenu u prevenciji, modulaciji ili liječenju dijabetesa, hiperglikemije, narušene tolerancije glukoze, gestacionog dijabetesa, inzulinske rezistencije, hiperinzulinemije, retinopatije, neuropatije, nefropatije, dijabetske bolesti bubrega, akutne bubrežne povrede, kardiorenalnog sindroma, akutnog koronarnog sindroma, odloženog zarastanja rana, ateroskleroze i njenih posledica, abnormalne srčane funkcije, kongestivne srčane slabosti, ishemije miokarda, moždanog udara, metaboličkog sindroma, hipertenzije, gojaznosti, masne jetre, dislipidemije, hiperlipidemije, hipertrigliceridemije, hiperholesterolemije, niskih lipoproteina visoke gustine, visokih lipoproteina niske gustine, nekardijačne ishemije, pankreatitisa, lipidnih poremećaja, neurodegenerativnih bolesti, kognitivnog oštećenja, demencije, bolesti jetre i ciroze jetre.
15. Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 10 za primjenu istovremeno, odvojeno ili redom sa dodatnim terapijskim agensom u prevenciji, modulaciji ili liječenju dijabetesa, hiperglikemije, narušene tolerancije glukoze, gestacionog dijabetesa, inzulinske rezistencije, hiperinzulinemije, retinopatije, neuropatije, nefropatije, dijabetske bolesti bubrega, akutne bubrežne povrede, kardiorenalnog sindroma, akutnog koronarnog sindroma, odgođenog zarastanja rana, ateroskleroze i njenih posljedica, abnormalne srčane funkcije, kongestivnog srčanog nedostatka, ishemije miokarda, moždanog udara, metaboličkog sindroma, hipertenzije, gojaznosti, masne jetre, dislipidemije, dislipidemije, hiperlipidemije, hipertrigliceridemije, hiperholesterolemije, niskih lipoproteina visoke gustine, visokih lipoproteina niske gustine, nekardijačne ishemije, pankreatitisa, lipidnih poremećaja, neurodegenerative bolesti, kognitivnog oštećenja, demencije, bolesti jetre i ciroze jetre.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261727262P | 2012-11-16 | 2012-11-16 | |
US201361777294P | 2013-03-12 | 2013-03-12 | |
EP13811645.4A EP2920165B1 (en) | 2012-11-16 | 2013-11-15 | Dihydropyrazole gpr40 modulators |
PCT/US2013/070215 WO2014078610A1 (en) | 2012-11-16 | 2013-11-15 | Dihydropyrazole gpr40 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20161631T1 true HRP20161631T1 (hr) | 2017-01-13 |
Family
ID=49876965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20161631TT HRP20161631T1 (hr) | 2012-11-16 | 2016-12-05 | Dihidropirazolni gpr40 modulatori |
Country Status (26)
Country | Link |
---|---|
US (1) | US9133163B2 (hr) |
EP (1) | EP2920165B1 (hr) |
JP (1) | JP6322203B2 (hr) |
KR (1) | KR102204804B1 (hr) |
CN (1) | CN104812748B (hr) |
AU (1) | AU2013344604B2 (hr) |
BR (1) | BR112015010779A2 (hr) |
CA (1) | CA2891574A1 (hr) |
CY (1) | CY1118365T1 (hr) |
DK (1) | DK2920165T3 (hr) |
EA (1) | EA026913B1 (hr) |
ES (1) | ES2606685T3 (hr) |
HR (1) | HRP20161631T1 (hr) |
HU (1) | HUE032401T2 (hr) |
IL (1) | IL238741A0 (hr) |
LT (1) | LT2920165T (hr) |
MX (1) | MX358499B (hr) |
PL (1) | PL2920165T3 (hr) |
PT (1) | PT2920165T (hr) |
RS (1) | RS55363B1 (hr) |
SG (1) | SG11201503558SA (hr) |
SI (1) | SI2920165T1 (hr) |
SM (1) | SMT201600410B (hr) |
TW (1) | TW201427971A (hr) |
UY (1) | UY35143A (hr) |
WO (1) | WO2014078610A1 (hr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014078611A1 (en) * | 2012-11-16 | 2014-05-22 | Bristol-Myers Squibb Company | Dihydropyrazole gpr40 modulators |
KR20160077213A (ko) | 2013-11-14 | 2016-07-01 | 카딜라 핼쓰캐어 리미티드 | 새로운 헤테로시클릭 화합물 |
DK3140296T3 (en) | 2014-05-07 | 2018-07-23 | Bristol Myers Squibb Co | PYRROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES SUCH AS DIABETES |
CA2948175A1 (en) * | 2014-05-07 | 2015-11-12 | Bristol-Myers Squibb Company | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes |
US10662171B2 (en) | 2014-08-08 | 2020-05-26 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
US10968193B2 (en) | 2014-08-08 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
EP3177285B1 (en) | 2014-08-08 | 2020-09-23 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
US11186565B2 (en) | 2017-03-31 | 2021-11-30 | Takeda Pharmaceutical Company Limited | Aromatic compound |
AU2019222644B2 (en) | 2018-02-13 | 2021-04-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
JP7105359B2 (ja) | 2018-07-13 | 2022-07-22 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
CN115490638A (zh) * | 2022-09-22 | 2022-12-20 | 哈尔滨理工大学 | 5-官能团化吡唑啉及其制备方法 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US20060148858A1 (en) | 2002-05-24 | 2006-07-06 | Tsuyoshi Maekawa | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity |
JP4579681B2 (ja) | 2002-07-09 | 2010-11-10 | ブリストル−マイヤーズ スクイブ カンパニー | 抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法 |
US7501440B2 (en) | 2003-03-07 | 2009-03-10 | Sanofi-Aventis Deutschland Gmbh | Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use |
US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
EP1637522A1 (en) * | 2004-09-16 | 2006-03-22 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds for reducing triglycerides in blood |
AU2005212817A1 (en) * | 2004-02-17 | 2005-08-25 | Laboratorios Dr. Esteve S.A. | Substituted pyrazoline compounds for reducing triglycerides in blood |
CA2558585C (en) | 2004-02-27 | 2010-10-12 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
JP4859665B2 (ja) | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
JP2007284350A (ja) | 2004-07-27 | 2007-11-01 | Takeda Chem Ind Ltd | 糖尿病治療剤 |
US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
EP1743894A1 (en) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments |
JP5084503B2 (ja) | 2005-07-29 | 2012-11-28 | 武田薬品工業株式会社 | シクロプロパンカルボン酸化合物 |
US7582803B2 (en) | 2005-09-14 | 2009-09-01 | Amgen Inc. | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders |
MX2008011615A (es) | 2006-03-14 | 2008-09-22 | Amgen Inc | Derivados de acidos carboxilicos biciclicos utiles para tratar trastornos metabolicos. |
EP2431367A3 (en) | 2006-06-27 | 2012-07-04 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds as GPR40 receptor modulators |
EP2064193A1 (en) | 2006-09-07 | 2009-06-03 | Amgen, Inc | Heterocyclic gpr40 modulators |
WO2008054675A2 (en) | 2006-10-31 | 2008-05-08 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
US7572934B2 (en) | 2007-04-16 | 2009-08-11 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
BRPI0818253A2 (pt) | 2007-10-10 | 2015-04-07 | Amgen Inc | Moduladores de gpr40 bifenil substituídos |
SI2202216T1 (sl) | 2007-10-26 | 2012-10-30 | Japan Tobacco Inc | Spiro obročna spojina in njena uporaba za medicinske namene |
AR070898A1 (es) * | 2008-03-18 | 2010-05-12 | Solvay Pharm Bv | Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6 |
US8236821B2 (en) * | 2008-05-19 | 2012-08-07 | Jenrin Discovery, Inc. | Substituted N-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
AU2010303670A1 (en) * | 2009-10-06 | 2012-03-29 | Bristol-Myers Squibb Company | Pyrrolidine GPR40 modulators |
AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
CN103547263B (zh) * | 2010-11-18 | 2015-12-09 | 詹里恩探索公司 | 对于治疗代谢性疾病,包括肥胖症和糖尿病有用的***素受体拮抗剂/反相激动剂 |
CA2818050A1 (en) * | 2010-11-26 | 2012-05-31 | Lupin Limited | Bicyclic gpr119 modulators |
US8791091B2 (en) | 2011-12-02 | 2014-07-29 | Bristol-Myers Squibb Company | Aryl dihydropyridinone and piperidinone MGAT2 inhibitors |
US9326218B2 (en) * | 2012-11-02 | 2016-04-26 | Telefonaktiebolaget L M Ericsson (Publ) | Base-station-to-base-station gateway and related devices, methods, and systems |
WO2014078611A1 (en) * | 2012-11-16 | 2014-05-22 | Bristol-Myers Squibb Company | Dihydropyrazole gpr40 modulators |
US8962660B2 (en) * | 2013-03-14 | 2015-02-24 | Bristol-Myers Squibb Company | Oxabicyclo [2.2.2] acid GPR120 modulators |
-
2013
- 2013-11-15 BR BR112015010779A patent/BR112015010779A2/pt not_active Application Discontinuation
- 2013-11-15 KR KR1020157015541A patent/KR102204804B1/ko active IP Right Grant
- 2013-11-15 UY UY0001035143A patent/UY35143A/es not_active Application Discontinuation
- 2013-11-15 SG SG11201503558SA patent/SG11201503558SA/en unknown
- 2013-11-15 CA CA2891574A patent/CA2891574A1/en not_active Abandoned
- 2013-11-15 DK DK13811645.4T patent/DK2920165T3/en active
- 2013-11-15 WO PCT/US2013/070215 patent/WO2014078610A1/en active Application Filing
- 2013-11-15 EP EP13811645.4A patent/EP2920165B1/en active Active
- 2013-11-15 HU HUE13811645A patent/HUE032401T2/en unknown
- 2013-11-15 LT LTEP13811645.4T patent/LT2920165T/lt unknown
- 2013-11-15 PL PL13811645T patent/PL2920165T3/pl unknown
- 2013-11-15 MX MX2015005735A patent/MX358499B/es active IP Right Grant
- 2013-11-15 RS RS20161061A patent/RS55363B1/sr unknown
- 2013-11-15 TW TW102141762A patent/TW201427971A/zh unknown
- 2013-11-15 SI SI201330340T patent/SI2920165T1/sl unknown
- 2013-11-15 EA EA201590954A patent/EA026913B1/ru not_active IP Right Cessation
- 2013-11-15 JP JP2015542798A patent/JP6322203B2/ja active Active
- 2013-11-15 CN CN201380059799.5A patent/CN104812748B/zh active Active
- 2013-11-15 ES ES13811645.4T patent/ES2606685T3/es active Active
- 2013-11-15 US US14/081,094 patent/US9133163B2/en active Active
- 2013-11-15 PT PT138116454T patent/PT2920165T/pt unknown
- 2013-11-15 AU AU2013344604A patent/AU2013344604B2/en not_active Ceased
-
2015
- 2015-05-11 IL IL238741A patent/IL238741A0/en not_active IP Right Cessation
-
2016
- 2016-11-14 SM SM201600410T patent/SMT201600410B/it unknown
- 2016-12-05 HR HRP20161631TT patent/HRP20161631T1/hr unknown
- 2016-12-16 CY CY20161101309T patent/CY1118365T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PL2920165T3 (pl) | 2017-04-28 |
SI2920165T1 (sl) | 2017-02-28 |
WO2014078610A1 (en) | 2014-05-22 |
EP2920165B1 (en) | 2016-09-28 |
CN104812748A (zh) | 2015-07-29 |
BR112015010779A2 (pt) | 2017-07-11 |
CA2891574A1 (en) | 2014-05-22 |
US9133163B2 (en) | 2015-09-15 |
SG11201503558SA (en) | 2015-06-29 |
UY35143A (es) | 2014-05-30 |
MX358499B (es) | 2018-08-23 |
JP2016500063A (ja) | 2016-01-07 |
PT2920165T (pt) | 2016-12-20 |
RS55363B1 (sr) | 2017-03-31 |
KR102204804B1 (ko) | 2021-01-18 |
LT2920165T (lt) | 2016-12-12 |
AU2013344604A1 (en) | 2015-07-02 |
ES2606685T3 (es) | 2017-03-27 |
HUE032401T2 (en) | 2017-09-28 |
TW201427971A (zh) | 2014-07-16 |
EA026913B1 (ru) | 2017-05-31 |
IL238741A0 (en) | 2015-06-30 |
KR20150082616A (ko) | 2015-07-15 |
AU2013344604B2 (en) | 2017-07-27 |
EA201590954A1 (ru) | 2015-08-31 |
CN104812748B (zh) | 2017-10-24 |
EP2920165A1 (en) | 2015-09-23 |
MX2015005735A (es) | 2015-09-16 |
DK2920165T3 (en) | 2017-01-16 |
CY1118365T1 (el) | 2017-06-28 |
US20140142139A1 (en) | 2014-05-22 |
SMT201600410B (it) | 2017-01-10 |
JP6322203B2 (ja) | 2018-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20161631T1 (hr) | Dihidropirazolni gpr40 modulatori | |
HRP20161011T1 (hr) | Aril dihidropiridinoni i piperidinoni kao inhibitori mgat2 | |
JP2014518853A5 (hr) | ||
JP2016500063A5 (hr) | ||
KR102610573B1 (ko) | 통풍 또는 고뇨산혈증과 관련된 증상의 치료 또는 예방을 위한 화합물, 조성물 및 방법 | |
AU2020203146A1 (en) | Combination therapies for the treatment of alzheimer's disease and related disorders | |
CA2798610A1 (en) | Bicyclic heteroaryl compounds as gpr119 modulators | |
HRP20160678T1 (hr) | Derivati 2-(1,2,3-triazol-2-il)benzamida i 3-(1,2,3-triazol-2-il)pikolinamida kao antagonisti receptora oreksina | |
JP2017508794A5 (hr) | ||
JP6238460B2 (ja) | 脂質異常症治療剤 | |
JP2009503107A5 (hr) | ||
HRP20141048T1 (hr) | Spojevi, pripravci i metode | |
SI3140296T1 (en) | PIROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES AS SUITABLE DISEASE | |
JP2010501567A5 (hr) | ||
JP2007532651A5 (hr) | ||
CN102119152A (zh) | 有机化合物 | |
RU2006105717A (ru) | Производные пиперазина и их применение в качестве терапевтических агентов | |
JP2014520809A5 (hr) | ||
HRP20110552T1 (hr) | DERIVATI 1,2,3-TRIAZOLA, NAMIJENJENI UPOTREBI KAO INHIBITORI STEAROIL-CoA-DESATURAZE | |
JP2017505293A5 (hr) | ||
JP2017508795A5 (hr) | ||
HRP20192275T1 (hr) | Novi spojevi 3,4-dihidro-2h-izokinolin-1-ona i 2,3-dihidro-izoindol-1-ona | |
RU2012134093A (ru) | 4-фенокси-никотинамиды или 4-фенокси-пиримидин-5-карбоксамиды | |
JP2009504712A5 (hr) | ||
RU2015142383A (ru) | Новейшие антагонисты trpa1-рецепторов |